Mary Jo Laffler

There is room for payers to cover large panel genetic testing but need limited labs w fixed costs, universal CT registry, Newcomer tells histology-agnostic panel at #ASCO19

Payers are stuck with a 1990s mentality, thinking about covering “experimental therapies,” Newcomer tells histology-agnostic panel at #ASCO19, but changing level of evidence.

Issues still remaining for histology-agnostic development, per @FDAOncology’s Blumenthal: role of next-gen sequencing vs companion Dx, using RWE, what level of evidence needed to exclude a specific histology where think not working #ASCO19

From a regulatory perspective, tissue-agnostic oncology is made easier by scientific understanding, large effect, and cancers where it’s hard to do trials. And there will be uncertainty, @FDAOncology’s Blumenthal tells #ASCO19 https://t.co/fdczvCQ4PO

For STS, “we should favor subtype-specific, biomarker-driven studies whenever possible,” Verweij concludes on Lartruvo failure. Might need innovative methodology for studies. #ASCO19

Verweij’s take on Lartruvo accelerated approval, including cost spent on ineffective drug. #ASCO19 https://t.co/rBbzhW3Wjr

Small numbers coupled w major heterogeneity in STS leads to type 1 error in Ph2, Verweij says on Lartuvo failure #ASCO19

“For whatever reason, just like other diseases OS is affected by multiple factors,” Verweij tells #ASCO19 on Lartuvi Ph3 fail.

Verweij discussing Lartruvo failure in Ph3, notes a critical issue for Ph2 in heterogeneous diseases is the small number of patients. slight differences can have great effect. #ASC019

Audience member at #ASCO19 drug pricing townhall: we’re on the Titanic, all this is irrelevant when we get to IO/IO combos and are paying millions for the way more common sickle cell disease. Need to focus on outcomes-based contracting, which focuses on accountability.

Nice explainer on international pricing index proposal, from an interesting town hall on drug pricing #ASCO19 https://t.co/CRfTtjNv7v

Atul Gawande’s reminder as #ASCO19 gets under way: “what you do could not matter more”

RT @Datamonitor_DF: Want to know what happened as ASCO over the weekend? Biomedtrackers weekend update is out https://t.co/zYNpPthRpN #ASCO…

RT @Datamonitor_JA: $PBYI gets win with $RHHBY Perjeta combo-.9% reduction in PFS, Nerlynx is small molecule-can compete effectively on pri…

RT @Cancer_talks: Damn even good old #cyclophosphamide is getting more expensive. Free market economics failing us in healthcare. #ASCO17 #…

RT @lindamahj: Sznol #ASCO17 on Lessons learned from immune therapy @prIME_Oncology @sitcancer sympo https://t.co/VRAlBcgiLS

RT @cancermd: Surprisingly low Response rate - < 5% with Pembrolizumab for TN metastatic breast cancer #ASCO17 https://t.co/XS0egtwCFE